MTEX MANNATECH INC
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1056358 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-6.6%
TTM net income YoY74.3%
TTM EPS YoY64.0%
Revenue 3-yr CAGR-8.3%
Net income 3-yr CAGR—
Margins
Gross margin75.7%
Operating margin0.9%
Net margin-0.4%
FCF margin-0.6%
EBITDA margin1.9%
Returns
ROE-7.0%
ROA-1.4%
ROIC (approx.)17.8%
Asset turnover3.33x
Leverage & solvency
Liabilities / assets81.3%
Debt / equity0.53x
Current ratio1.18x
Interest coverage2.00x
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio-0.7%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $108.04M | $117.87M |
| Cost of revenue | $27.08M | $26.41M |
| Gross profit | $80.96M | $91.46M |
| R&D expense | $800,000 | $700,000 |
| SG&A expense | $39.66M | $41.72M |
| Operating income | -$426,000 | $1.43M |
| Interest expense | $406,000 | $279,000 |
| Pretax income | -$2.89M | $3.74M |
| Income tax | $12.32M | $1.25M |
| Net income | -$15.21M | $2.49M |
| EBITDA | $666,000 | $2.96M |
| EPS (basic) | -8.00 | 1.32 |
| EPS (diluted) | -8.00 | 1.32 |
| Weighted avg. shares (diluted) | 1.90M | 1.89M |
| Banking | ||
| Net interest income | — | -$279,000 |
| Balance sheet | ||
| Cash & equivalents | $6.18M | $11.40M |
| Receivables | $1,000 | $19,000 |
| Inventory | $10.12M | $10.40M |
| Current assets | $20.58M | $26.12M |
| PP&E, net | $3.14M | $2.71M |
| Intangibles | $237,000 | $237,000 |
| Total assets | $29.99M | $36.06M |
| Current liabilities | $18.73M | $20.90M |
| Long-term debt | $2.75M | — |
| Total debt | $2.75M | — |
| Total liabilities | $35.22M | $27.44M |
| Shareholders' equity | -$5.22M | $8.61M |
| Net debt | -$3.44M | — |
| Shares outstanding | 1.90M | 1.88M |
| Cash flow statement | ||
| Operating cash flow | -$2.96M | $2.26M |
| Capital expenditure | $1.35M | $297,000 |
| Free cash flow | -$4.32M | $1.96M |
| Investing cash flow | -$1.35M | -$285,000 |
| Financing cash flow | -$561,000 | $1.96M |
| Depreciation & amortization | $1.09M | $1.53M |
| Stock-based compensation | $379,000 | $291,000 |
| Dividends paid | — | $0 |
| Share buybacks | — | $0 |
Free plan shows the latest 2 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.